At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,100 enrolled
Drug / intervention
NeuroAid +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double Blind, Placebo Controlled, Randomized, Multicenter Study to Investigate CHInese Medicine NeuroAid Efficacy on Stroke Recovery
In Brief
A Phase 3 clinical trial evaluating NeuroAid and NeuroAid matched Placebo for Cerebral Infarction and Stroke. Completed, enrolled 1,100 participants across 24 sites in 6 countries.
Detailed Summary
CHIMES is a double blind, placebo controlled, randomized, multicenter study to test the hypothesis that NeuroAid is superior to placebo in reducing neurological deficit and improving functional outcome in patients with cerebral infarction of an intermediate range of severity.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCerebral Infarction, Stroke
CountriesHong Kong, Malaysia, Philippines, Singapore, Sri Lanka, Thailand
CollaboratorsNational Medical Research Council (NMRC), Singapore
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2007
First PostedNov 2007
Primary CompletionAug 2012
TodayJul 2026
First PostedNov 7, 2007
Enrollment StartMay 1, 2007
Primary CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 18.7 years ago
Interventions
NeuroAiddrug
4 capsules 3 times daily, for three months
NeuroAid matched Placebodrug
NeuroAid matched Placebo, 4 capsules 3 times daily, for three months